Could a common cancer drug prevent relapse after transplant?

NCT ID NCT03850418

Recruiting now Disease control Sponsor: Henry Ford Health System Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether low-dose azacitidine can help maintain donor cell levels (chimerism) in patients with MDS, AML, or related blood cancers after an allogeneic stem cell transplant. About 43 adults whose donor cell levels are dropping will receive azacitidine for at least 4 cycles. The goal is to see if this can reduce the risk of cancer relapse without increasing graft-versus-host disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: azacitidine
What this could lead to: If it works, this could offer a way to prevent relapse in patients with myeloid cancers after a stem cell transplant.
What could go wrong: This is a small, early-phase trial with only 43 participants. The drug may not improve chimerism or could cause side effects like low blood counts or graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia chronic myelomonocytic leukemia myelodysplastic syndrome myeloid neoplasm myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOID MALIGNANCY

Contacts and locations

Locations

Henry ford hospital
RECRUITING

Detroit, Michigan, 48202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.